ReviewInternational journal of molecular sciences2026
Emerging Regenerative Medicine for Spinal Cord Injury: Spinal Cord Organoids-on-a-Chip.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Spinal cord injury (SCI) is among the most devastating neurological conditions worldwide, imposing substantial clinical, psychological, and socioeconomic burdens on affected individuals and healthcare services. However, a translational gap persists between preclinical findings and therapeutically relevant human applications, partly involving the limitations of conventional two-dimensional culture systems, which inadequately reproduce the complex three-dimensional structure of the spinal cord; and partly due to the fact that animal models differ from humans phylogenetically and physiologically. Recent advances in three-dimensional spinal cord organoids and organoid-on-a-chip microfluidic platforms have provided new opportunities to model human spinal cord biology with greater fidelity. This review discusses the clinical and socioeconomic burden of SCI, identifies the limitations of existing experimental platforms, and explains how microfluidics and scaffold technologies may converge to accelerate the development of regenerative therapies. It also summarizes methodological innovations, recent advances, unresolved challenges, and future prospects in this rapidly evolving field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.